Showing 1241-1250 of 7691 results for "".
Business Advisor: Protect Your Practice With Online Reputation Management Strategies
https://practicaldermatology.com/topics/general-topics/business-advisor-protect-your-practice-with-online-reputation-management-strategies/21943/Online communication has affected how patients view physicians and practices. Learn how to know who is saying what about you on the Internet and what to do about itTake 5: New Developments in the Realm of STIs and STDs
https://practicaldermatology.com/columns/take-5/take-5-new-developments-in-the-realm-of-stis-and-stds/21969/New data and recent advancements highlight the importance of education and prevention.Clinical Focus: Psoriasis: New Data on Comorbidities Associated with Psoriasis
https://practicaldermatology.com/topics/psoriasis/new-data-on-comorbidities-associated-with-psoriasis/21979/With data mounting, it is essential that dermatologists monitor all patients who may be at risk for comorbidities and provide referrals when indicated.Take 5: Strategies to Fight Skin Cancer Trends
https://practicaldermatology.com/columns/take-5/take-5-strategies-to-fight-skin-cancer-trends/22035/On the 25th anniversary of the renowned ABCDE's of Melanoma, a contributor to the guidelines shares strategies to improve detection and bolster prevention efforts.GLP-1 Receptor Agonists and the Aesthetic Patient: Considerations for the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-and-the-aesthetic-patient/48900/The impact of glucagon-like peptide-1 agonists (GLP-1), such as semaglutide, tirzepatide and liraglutide, has transformed the healthcare industry and, in particular, aesthetic dermatology. The most common intended use of these medications, namely diabetes management and weight loss, can lead to a muGLP-1RAs and the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1ras-and-the-dermatologist/48885/We are only beginning to understand the implications of GLP-1s for skin and systemic health. These medications are here to stay, and dermatology must be part of the conversation.A Guide to Building Lifelong Patient Loyalty
https://practicaldermatology.com/issues/october-2025/a-guide-to-building-lifelong-patient-loyalty/39758/Interest in medical aesthetic treatments continues to grow and signs indicate that demand will remain strong. Today’s patients are more informed and educated than ever and are seeking personalized, high-quality experiences.Cutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuPreparing for Private Equity: Benefits and Drawbacks
https://practicaldermatology.com/issues/september-2025/preparing-for-private-equity-benefits-and-drawbacks/37629/Over the past decade, the health care industry has emerged as a prime target for private equity (PE) investment.Busy by Design Plans: How to Use Downtime to Drive Revenue and Make Uptime Smoother for Your Team
https://practicaldermatology.com/issues/september-2025/busy-by-design-plans-how-to-use-downtime-to-drive-revenue-and-make-uptime-smoother-for-your-team/37641/In today’s fast-paced dermatology industry, treatments can sometimes feel more transactional than transformational.